Introducing the first and only clinically validated biomarker for metastatic colorectal cancer.

PersonaCRC assesses the risk of spread, recurrence, and overall survival, to help clinicians identify the most effective treatment strategies and improve patient outcomes.

Patients diagnosed with metastatic colorectal cancer in the liver face a wide range of treatment options. By integrating genetic data with clinical insights and an AI-driven platform, PersonaCRC enables clinicians to tailor therapies to each patient’s unique cancer profile.

The utilization of PersonaCRC improves patient outcomes and reduces unnecessary treatments, through the delivery of evidence-based prognostic and therapeutic recommendations and an unmatched 96% accuracy in colorectal tumor classification.

PersonaCRC Highlights:

• 96% accuracy in tumor classification

• 60% difference in 5 year overall survival between groups vs oncologists’ prediction of 50/50 chance of survival

• Proven success: validated results in randomized Phase 3 EPOC trial

• 25% identification of subset of patients with excellent survival after treatment

Precision Risk Assessment

Move beyond imprecise survival prediction. Our AI-powered test provides accurate risk stratification based on your patient's unique tumor biology and clinical features.

Advanced Biomarker Technology

Biomarker assays analyze mRNA data to classify tumors into molecular subtypes for personalized treatment guidance.

Clinically Validated Results

Proven success in randomized Phase 3 trials. Identify patients with excellent survival potential and guide therapy selection with confidence.

PersonaCRC is used to guide the personalization of cancer treatments based upon our integrated prognostic risk classification to drive improvements in overall survival and potentially lead to cure. 

Ordering Process:

1. Physician Orders Test

   The treating physician orders the PersonaCRC test for their patient with the test request form (TRF)

2. Tissue Sample Sent

   The liver metastasis tissue is sent for RNA sequencing to your sequencing partner or Protean BioDiagnostics. Data are sent from sequencing partner to Protean BioDiagnostics via secure AWS platform. No additional medical procedures are required.

3. AI Analysis

   The PersonaDx neural network analyzes clinical and genomic data to determine molecular subtype and risk classification.

4. Results & Treatment Plan

   Physician receives results from Protean BioDiagnostics and reviews personalized treatment recommendations with patient